Skip to main content
. 2022 Jul 26;45(9):2037–2045. doi: 10.2337/dc21-2119

Table 1.

EDIC participant characteristics at the time of the physical function assessment (2018–2019)

All Women Men P *
N 1,094 522 572
Study design
 DCCT conventional treatment group 518 (47.3) 243 (46.6) 275 (48.1) 0.657
 DCCT secondary intervention cohort 545 (49.8) 256 (49.0) 289 (50.5) 0.668
Demographics
 Age (years) 59.5 ± 6.8 59.0 ± 7.1 60.0 ± 6.4 0.018
 Age <65 years 854 (78.1) 410 (78.5) 444 (77.6) 0.768
 Education 0.450
  Graduate school 276 (25.3) 130 (25.0) 146 (25.6)
  College graduate 415 (38.0) 190 (36.5) 225 (39.4)
  Some college or trade school 304 (27.8) 148 (28.4) 156 (27.3)
  Secondary school graduate or less 97 (8.9) 53 (10.2) 44 (7.7)
 Employment 0.088
  Employed 760 (69.9) 353 (67.6) 407 (72.0)
  Retired 232 (21.3) 119 (22.8) 113 (20.0)
  Unemployed 44 (4.0) 28 (5.4) 16 (2.8)
  Disabled 51 (4.7) 22 (4.2) 29 (5.1)
Nonglycemic characteristics
 Current smoker 91 (8.3) 35 (6.7) 56 (9.8) 0.083
 Heavy alcohol use (≥27 g/day) 60 (5.5) 14 (2.7) 46 (8.1) <0.001
 BMI (kg/m2) 29.2 ± 5.8 29.1 ± 6.4 29.4 ± 5.3 0.057
 BMI category 0.001
  Underweight 5 (0.5) 5 (1.0) 0 (0.0)
  Normal 263 (24.0) 147 (28.2) 116 (20.3)
  Overweight 403 (36.8) 173 (33.1) 230 (40.2)
  Obese 423 (38.7) 197 (37.7) 226 (39.5)
 Total MoCA score 26.2 ± 2.6 26.5 ± 2.6 25.9 ± 2.6 <0.001
 Psychological distress (GSI ≥63) 86 (8.1) 41 (8.2) 45 (8.0) 0.989
Glycemic characteristics
 Duration of type 1 diabetes (years) 37.9 ± 4.9 38.1 ± 5.0 37.8 ± 4.8 0.574
 Time-weighted mean DCCT/EDIC HbA1c (%) 7.9 ± 0.9 7.9 ± 0.9 7.9 ± 0.9 0.095
 Time-weighted mean DCCT/EDIC HbA1c (mmol/mol) 62.8 ± 9.8 63.3 ± 9.7 62.4 ± 9.8 0.095
 EDIC HbA1c (%) 7.9 ± 0.9 7.9 ± 0.9 7.8 ± 0.9 0.102
 EDIC HbA1c (mmol/mol) 62.6 ± 10.3 63.1 ± 10.4 62.1 ± 10.3 0.102
 Current HbA1c (%) 7.8 ± 1.2 7.9 ± 1.2 7.6 ± 1.1 <0.001
 Current HbA1c (mmol/mol) 61.2 ± 12.8 62.5 ± 12.9 60.0 ± 12.6 <0.001
 Any severe hypoglycemia (≥1 vs. 0 cumulative events) 546 (50.5) 255 (49.3) 291 (51.6) 0.456
Micro- and macrovascular complications
 Any nonfatal CVD§ 172 (15.7) 73 (14.0) 99 (17.3) 0.154
 Any PDR 284 (26.0) 126 (24.1) 158 (27.6) 0.214
 Any reduced eGFR 88 (8.1) 33 (6.3) 55 (9.6) 0.058
 Diabetic peripheral neuropathyǁ 277 (26.9) 102 (20.9) 175 (32.2) <0.001
 Cardiac autonomic neuropathy 374 (35.5) 182 (36.6) 192 (34.4) 0.493

Data are means ± SD or n (%). PDR, proliferative diabetic retinopathy.

*

P values evaluate difference at α = 0.05 level between the N = 522 female and N = 572 male participants. Pearson χ2 test with Yates’ continuity correction is used for binary and categorical variables, and Wilcoxon rank sum test with continuity correction is used for continuous variables.

MoCA was assessed in N = 1,049 active participants (n = 495 female, n = 554 male), and mild cognitive impairment was defined as a MoCA score ≤21. n = 58 participants scored ≤21.

Severe hypoglycemia was defined as events leading to coma or seizure documented by self-report for the 3-month period prior to each annual study visit. Cumulative refers to the running sum of all events.

§

CVD events were considered only if the event occurred before the physical function assessment.

ǁ

Diabetic peripheral neuropathy was assessed in N = 1,031 participants (n = 487 female and n = 544 male).

Cardiac autonomic neuropathy was assessed in N = 1,055 participants (n = 497 female and n = 558 male).